This content is machine translated VERTIS-CV Study Evidence base of SGLT-2 inhibitors supplemented by further piece of the mosaic Ertugliflozin as an add-on to standard treatment was shown to be non-inferior to placebo in terms of MACE (major adverse cardiac event) in this large-scale international study. This confirmed the…
